Cellular Immunotherapy to Target HER-2 for Oncology is under clinical development by ImmunoRestoration and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy to Target HER-2 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cellular Immunotherapy to Target HER-2 for Oncology overview

Cellular immunotherapy is under development for treatment of patients who are undergoing surgery for ductal carcinoma in situ of the breast and invasive breast cancer post neoadjuvant chemotherapy, triple negative breast cancer, HER2- breast cancer and HER2+ breast cancer. The drug candidate is administered as intranodal, intratumoral and intralesional injections. The drug candidate comprises of dendritic cells are pulsed with recombinant HER2/neu peptides.

ImmunoRestoration overview

ImmunoRestoration is a bio pharmaceutical company that develops and commercializes immunotherapeutic cancer vaccines. The company is investigating therapies to treat Ductal carcinoma in situ (DCIS), invasive breast cancer, glioblastoma, melanoma, pancreatic, prostate and gastric cancer. It utilizes ICAIT (Immune Conditioning via Activated Innate (autologous) Transfer), an integrated dendritic cell-based immunization system that helps patients in restoring their immune response. The company works in partnership with Moffitt Cancer Center, Pennies in Action, University of Pennsylvania and The Werner and Mary Henle Foundation. ImmunoRestoration is headquartered in Warminster, Pennsylvania, the US.

For a complete picture of Cellular Immunotherapy to Target HER-2 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.